| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 71.43 | 44.8% |
| Total Income | 71.43 | 44.8% |
| Expenditure | 152.47 | 10.6% |
| PBT | -79.71 | 32.5% |
| Net Profit | -79.05 | 31.9% |
| OPM | — | |
| NPM | — | |
| EPS | -0.19 | 47.2% |
Iovance Reports 1Q26 Revenue ~$71M, Up ~45% Y-o-Y
07 May 2026 · 7 May, 6:52 pm
Summary
Iovance Biotherapeutics reported a strong first quarter in 2026, with total product revenue reaching approximately $71 million, a 45% increase year-over-year. The company's U.S. Amtagvi revenue was approximately $60 million, while global Proleukin revenue was approximately $11 million. Iovance provided guidance for 2Q26 revenue between $86 million and $88 million and FY26 revenue between $350 million and $370 million. Initial data from a trial in metastatic serous endometrial cancer showed a 40% confirmed objective response rate.
Key Highlights
- 1
Iovance Biotherapeutics reported total product revenue of approximately $71 million for 1Q26, reflecting an increase of approximately 45% compared to 1Q25.
- 2
U.S. Amtagvi revenue was approximately $60 million in 1Q26.
- 3
Global Proleukin revenue was approximately $11 million in 1Q26.
- 4
The company anticipates total product revenue for 2Q26 to be between $86 million and $88 million.
- 5
Iovance projects total product revenue for FY26 to range from $350 million to $370 million.
- 6
Initial data in previously treated metastatic serous endometrial cancer showed a confirmed objective response rate of 40%.
Management Comments
Frederick Vogt
We are accelerating the adoption and commercial expansion for Amtagvi after record high demand. Iovance is well positioned through 2026 for long-term revenue growth, while advancing multiple ongoing and new clinical trials, including our registrational trial in advanced sarcomas now underway and encouraging initial data reported today for lifileucel in metastatic serous endometrial cancer. Internal manufacturing efficiencies, operational improvements, and cost reductions will benefit gross margin and propel future profitability, sustainable growth, and long-term value for patients and shareholders.
Informational and educational content only. Not investment advice.